AI assistant
StageZero Life Sciences Ltd. — Earnings Release 2021
Aug 12, 2021
44586_rns_2021-08-11_c1055059-4951-4567-9e46-84204249365b.pdf
Earnings Release
Open in viewerOpens in your device viewer
StageZero to Issue Q2 2021 Financial Results and Hold Conference Call on Tuesday, August 17
TORONTO, ON / ACCESSWIRE / August 11, 2021 / StageZero Life Sciences
("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its second quarter 2021 operational results before the market open on Tuesday, August 17, 2021. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EST on Tuesday, August 17, 2021, to review the operational results and discuss business developments.
Analyst and Investor Call
Event Date : Tuesday, August 17, 2021 Time: 8:30 a.m. EST
Webcast Link : https://www.webcaster4.com/Webcast/Page/2082/42373 Participant Numbers: Toll Free: +1 844-602-0380
International: +1-862-298-0970
Replay Number: Toll Free: +1-877-481-4010
International: +1-919-882-2331 Replay Passcode: 42373
About StageZero Life Sciences Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company’s next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero’s full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.
STAGEZERO LIFE SCIENCES LTD.
James Howard-Tripp Chairman & CEO
For further information please contact:
Rebecca Greco Investor Relations Tel: 1-855-420-7140 ext. 1838 [email protected]